AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02124265 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CeraLyte 90
Description: 1. This is a prospective pilot study of patients with moderate-major burn wounds (20-65% TBSA).~2. Patients who meet inclusion/exclusion criteria will be enrolled in the study upon admission to the Burn Unit.~3. Fluid requirements will be calculated according to the Parkland Formula (4 cc/kg/% Total Body Surface Area) administered over 24 hours since time of injury.~5. Patients will be monitored according to standard of care.~a. If gastric residuals are >300cc, ORT will be stopped and only IV fluid resuscitation will be used.
Study NCT00490282 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Intensity Modulated Radiation Therapy
Description: IMRT Treatment Over 6-7 Weeks
Study NCT00490282 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Adaptive Radiotherapy
Description: ART Treatment Over 6-7 Weeks
Study NCT06065566 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: L-alanyl-L-glutamine dipeptide
Description: 1. Once the candidate patients undergo surgery for cardiac surgery with and without cardiopulmonary bypass, the inclusion criteria will be verified. Once their inclusion in the study has been accepted, the patient must sign their informed consent letter and will be randomly assigned by closed envelope, to a study group or to a control group. The patient's weight and height will be taken once he accepts inclusion in the study and the data collection notebook will be filled.~A. Study group: patients undergoing cardiac surgery with and without cardiopulmonary bypass, who will receive the dipeptide L-alanyl-L-glutamine, at a dose of 0.4 g / kg of weight 6 hours before the surgical intervention.
Study NCT06065566 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 1. Once the candidate patients undergo surgery for cardiac surgery with and without cardiopulmonary bypass, the inclusion criteria will be verified. Once their inclusion in the study has been accepted, the patient must sign their informed consent letter and will be randomly assigned by closed envelope, to a study group or to a control group. The patient's weight and height will be taken once he accepts inclusion in the study and the data collection notebook will be filled.~B. Control group: patients undergoing cardiac surgery with and without cardiopulmonary bypass, who will receive the placebo in the form of saline solution in a volume similar to the control 6 hours before the surgical intervention.
Study NCT03612661 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Guided Self-Help
Description: Participants in the GSH condition will follow the intuitive eating content through self-guided study, with eight weekly scheduled phone calls with an interventionist (\~20 minutes each). Interventionists will review homework assignments, answer questions, and reinforce adherence. The intervention materials are the same as the group and also focus on cultivating attunement to bodily sensations and fostering self-compassion to improve physical and mental health.
Study NCT00736307 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cultured limbal stem cells Transplantation
Description: Transplantation of cultivated limbal epithelium on amniotic membrane
Study NCT03253549 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SMArTVIEW
Description: Remote automated, continuous monitoring in hospital after cardiac or vascular surgery, followed by 30-day at home monitoring, daily nurse video visits and a self-management training program.
Study NCT01741766 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Stretching Training
Description: The stretching training intervention consists of 38 whole-body stretching exercises, 3 times per week for 8 wk. Each stretch will be held in place for 30 seconds, with a 15 seconds of rest in between stretches.
Study NCT00443079 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IdB 1016 (Siliphos)
Description: 1 pill 3 times daily x 6 weeks
Study NCT00443079 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Matched placebo
Description: 1 pill 3 times daily x 6 weeks
Study NCT03660774 — intervention group
Intervention type: OTHER
Intervention: No treatment given
Description: The participants will undergo a brief physical examination focused on neurologic function (muscle function, sensation, coordination, walking). Parents will be asked by the study team or the psychologist about their children and will complete several commonly used standard surveys about brain development, thinking, behavior, and decision making. The participants will also engage with the psychologist to evaluate development or thinking (IQ), and depending on their age they may be asked to complete one or more commonly used standard surveys about behavior and decision making.
Study NCT03798509 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Human CD19 targeted T Cells Injection
Description: Autologous genetically modified anti-CD19 CAR transduced T cells
Study NCT01522001 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Shared Care model
Description: * First visit at cardiac ambulatory approximately 14 days after discharge includes physician examination by cardiologist and counseling from nurse specialized in cardiac rehabilitation.~* Dietary counseling with dietician~* Exercise (1 hour, 2 timer pr week for 12 weeks)~* Smoking cessation if smoker with educated smoking cessation instructor~* Patient education and psychosocial support in 2 individual consultations and 8 group based consultations with experienced nurse~* Examination by the patient´s general practitioner 8-12 weeks after discharge.
Study NCT04663451 — intervention group
Intervention type: RADIATION
Intervention: radioacive iodine therapy
Description: Hyperthyroid patients who have undergone radioactive iodine treatment to cure them from their hyperthyroidism.
Study NCT00967382 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: dalteparin sodium
Description: Subject's randomize to treatment arm will receive dalteparin sodium 5,000 IU s.c. daily starting on randomization day until 20 weeks gestational age then;~dalteparin sodium 5,000 IU s.c. bid from 20 weeks to onset of labour or 37 weeks gestation (discontinued at the discretion of the investigator/obstetrician)~Within 24 hours of delivery, all subject's, regardless of randomization allocation will receive dalteparin sodium 5,000 IU s.c. daily for 6 weeks post-partum
Study NCT02218879 — intervention group
Intervention type: DRUG
Intervention: Tecfidera
Description: Oral Tecfidera 240 mg bid
Study NCT02841176 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Thermography
Description: Thermographic imaging of arthritic joints will be performed at baseline and within 5 days after the participant's 2nd and 4th doses of monthly Golimumab
Study NCT02442570 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: recombinant human alpha B-crystallin
Description: intravenous injections
Study NCT02442570 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo comparator
Description: intravenous injection
Study NCT03743805 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Flumazenil
Description: 0.2 mg IV push, which may be repeated every 20 minutes for up to a total of 1 mg
Study NCT03743805 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Naloxone
Description: 0.4 mg IV push, which may be repeated every 2 minutes for up to a total of 2 mg
Study NCT03255161 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: community health worker-audiologist communication education and support group
Description: A 5-week educational program on hearing loss, communication strategies, and peer support facilitated by community health workers supervised by an audiologist.
Study NCT04155216 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Relaxation and guided imagery program
Description: Listening to a relaxation and guided imagery program for 25 minutes during hemodialysis treatments.
Study NCT02464774 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Breast-Conserving Therapy
Description: Patients undergo lumpectomy with surgical axillary staging with all lesions resected to negative margins.
Study NCT02464774 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Mastectomy
Description: Patients undergo mastectomy with surgical axillary staging with all lesions resected to negative margins.
Study NCT04617132 — intervention group
Intervention type: BEHAVIORAL
Intervention: MBCT/MBSR
Description: This intervention teaches the practice of mindfulness - being aware of the present moment without judgement - to help reduce the emotional reactivity to thoughts and bodily sensations, which prevents downward spirals into depression, anxiety, or fear.
Study NCT02573922 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: oxycodone-naloxone
Study NCT02573922 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxycodone
Study NCT03591367 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: MicroRNAs-155
Description: Quantitative analysis of cell-free miR-155 using RT-qPCR.
Study NCT03591367 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Human telomerase reverse transcriptase
Description: Analysis TERT by TERT messenger RNA (mRNA)expression by reverse transcription-quantitative polymerase chain reaction.
Study NCT02296190 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etripamil
Description: intranasal administration via 4 prefilled Aptar Pharma Unit-Dose Spray devices
Study NCT02296190 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: intranasal administration via 4 prefilled Aptar Pharma Unit-Dose Spray devices
Study NCT02178566 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Inhaled Treprostinil
Description: A dose of inhaled treprostinil or placebo will be administered to all study participants prior to each of their Pulmonary Rehab sessions. Three puffs of inhaled treprostinil dose will be administered each time to all patients .
Study NCT02178566 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Inhaled Treprostinil
Description: A dose of inhaled treprostinil or placebo will be administered to all study participants prior to each of their Pulmonary Rehab sessions. Three puffs of inhaled treprostinil dose will be administered each time to all patients .
Study NCT01857401 — intervention group
Intervention type: OTHER
Intervention: No intervention, observational study only
Description: No intervention. We are collecting blood for an ex vivo study
Study NCT04589533 — intervention group
Intervention type: OTHER
Intervention: educational program
Description: The educational program will be based on: a outreach visit (a 3-h face-to-face meeting between a trained diabetes specialist from outside the Center and the staff of the Center itself) and a distance learning (FAD).The educational programme will be focused on current Diabetes Guidelines recommendations and based on possible deviations from the best clinical practice observed during phase1
Study NCT02081950 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Enoxaparin sodium
Description: comparison of 2 different administration of drug
Study NCT02464774 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adjuvant Chemotherapy
Description: Patients with stage I and II receive adjuvant chemotherapy using TC and TAC regimen respectively.
Study NCT04780373 — intervention group
Intervention type: OTHER
Intervention: data collection
Description: clinical data collection
Study NCT02464774 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Adjuvant Chemotherapy
Description: Patients with stage I and II receive adjuvant chemotherapy using TC and TAC regimen respectively.
Study NCT02464774 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation Therapy
Description: N0: Radiation therapy to whole breast (+boost to tumor bed) or consideration of partial breast irradiation in selected patients; (2) N1: Radiation therapy to whole breast (+boost to tumor bed), infraclavicular region, and supraclavicular area with or without radiation therapy to internal mammary nodes.
Study NCT01578473 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin D2
Description: oral softgel 2000 IU once daily 9 months
Study NCT01578473 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin E
Description: oral softgels 400 IU and 200 IU 1 softgel of 400 IU daily~1 softgel of 200 IU daily 9 months
Study NCT01578473 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Testosterone Pellets
Description: subcutaneous implantation pellets 75 mg based on testosterone levels from resulting bloodwork 9 months
Study NCT04786340 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Active: WST-057 4mL (146 mg pirenzepine free base monohydrate) topical solution
Description: WST-057
Study NCT04786340 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo: WST-057 4mL topical solution
Description: Placebo
Study NCT04075266 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ocrelizumab
Description: Ocrelizumab is administered as two infusions of half the dose given 14 days apart for the first dose, then subsequent doses are administered as a single infusion every 24 weeks.~Cohort 1: total dose of 300 mg Cohort 2: total dose of 600 mg Cohort 3 and 4: additional dose level(s) may be lower than 300 mg, between 300 mg and 600 mg, or higher than 600 mg, but will be no higher than 1200 mg
Study NCT01016301 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Pharmacist service
Description: Medication Review, medication report
Study NCT04176380 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: RAPA-201 Autologous T cells
Description: Autologous rapamycin resistant Th1/Tc1 cells
Study NCT03245138 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Endoscopic Third Ventriculostomy
Description: patients receive an endoscopic third ventriculotomy as surgical procedure
Study NCT03245138 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Ventriculo-Peritoneal Shunting
Description: patients receive an ventriculo-peritoneal shunt as surgical procedure
Study NCT04182711 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Device
Description: Phase 1: Time taken for each patient is 25 mins Phase 2: Time taken for each patient is 30 mins
Study NCT02009202 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: polyethylene glycol
Study NCT01257113 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: supervised exercise
Description: This group will receive 10 classes of supervised exercise in the 6 weeks intervention. In this classes the patients will be with a physiotherapist that will adjust their home-exercise program and make sure they do the exercises in a good way. They will receive 4-6 exercises they shall do 3 times with 30 repetitions, 2 times every day. If necessary, they should also do stretching exercises
Study NCT01257113 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: homebased exercises
Description: This group will receive 1 class of supervised exercise at the beginning of the 6 weeks intervention. In this class the patients will be with a physiotherapist that will put together a home-exercise program and make sure they do the exercises in a good way. They will receive 4-6 exercises they shall do 3 times with 30 repetitions, 2 times every day. If necessary, they should also do stretching exercises
Study NCT03442608 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Zoll 2000 and/or CureWrap 3500 cooling system
Description: Device(Zoll 2000 and/or CureWrap 3500 cooling system),lasting 5 to 7 days, the core temperature will be controlled in 33-35 degree.
Study NCT03442608 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Zoll 2000 and/or CureWrap 3500 cooling system
Description: Device(Zoll 2000 and/or CureWrap 3500 cooling system),lasting 5 to 7 days, the core temperature will be controlled in 33-35 degree.
Study NCT02009202 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: picosulphate
Study NCT04658641 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Boston Scientific: Study tool computer
Description: Compare clinical outcome measurements of complex pulse shapes to standard clinical pulse shape
Study NCT04658641 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Boston Scientific: Study tool computer
Description: Compare clinical outcome measurements of complex pulse shapes to standard clinical pulse shape
Study NCT02282631 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Incentive scheme
Description: Children who actively travel to school, full or partway, enter a weekly £5 voucher draw, whereby chances of winning are proportional to the number of trips as reported by the parent.
Study NCT03344224 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: laboratory test
Description: laboratory test
Study NCT02119793 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: YVOIRE contour
Description: YVOIRE contour injection into the anteromedial malar region
Study NCT01223625 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rosuvastatin 5mg/day
Description: Rosuvastatin 5mg/day
Study NCT01223625 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rosuvastatin 40mg/day
Description: Rosuvastatin 40mg/day
Study NCT02129413 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Delta system
Study NCT01826578 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: using only one port for laparoscopic surgery
Description: using only one port for laparoscopic surgery
Study NCT03702335 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Dietary Counselling
Description: Intervention group will be given a comprehensive dietary guidance on how to choose healthier options when eating out, as well as how to personally prepare a healthy meals.
Study NCT02460692 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebos
Description: Administration of vaporized cannabis plus either dronabinol or placebo pill
Study NCT02460692 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: dronabinol
Description: Administration of vaporized cannabis plus either dronabinol or placebo pill
Study NCT03460405 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Vi-DT Vaccine
Description: 1 dose of Vi-DT Vaccine
Study NCT02460692 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vaporized Cannabis 3.7% THC/5.6% CBD
Description: Administration of vaporized cannabis plus either dronabinol or placebo pill
Study NCT03460405 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Vi Polysaccharide Vaccine
Description: 1 dose of Vi Polysaccharide Vaccine
Study NCT03460028 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Yoga Condition
Description: Participants randomized to the Yoga Condition will participate in an integrated yoga program consisting of yoga postures, breathing exercises, and concentration/meditation practices.
Study NCT00002832 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Filgrastim
Description: Subcutaneously (SQ) daily every 12 hours starting 2-4 days prior to first PBSC collection then daily starting 1 day after PBSC infusion until blood counts recover.
Study NCT00002832 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclosporine
Description: IV daily on day -2, then orally once dose is tolerable, dose may be escalated.
Study NCT00002832 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Decitabine
Description: IV for 6 hours every 12 hr for 5 days.
Study NCT00002832 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Allogeneic Bone Marrow Transplantation
Description: Stem cell infusion on Day 0.
Study NCT00002832 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Peripheral Blood Stem Cell Transplantation
Description: Peripheral blood stem cells (PBSC) are administered 5 days after last dose of decitabine.
Study NCT01896401 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: InSeal's Vascular Closure Device
Study NCT02919722 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Music Therapy
Description: The majority of each study session will be spent engaging in music therapy: playing live music with a music therapist with the help of an occupational therapist. At the beginning and end of each session subjects will complete 2 assessments.
Study NCT01217008 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GRNOPC1
Description: One injection of 2 million GRNOPC1 cells.
Study NCT02841176 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Golimumab
Description: Participants will start monthly Golimumab after their baseline visit
Study NCT00333554 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: DHA Treatment
Description: DHA study treatment given on daily basis to nursing mother (breast milk) or baby as either formula, or capsules (removing content and mixing with food) depending on age of child.
Study NCT03513757 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: propofol
Description: propofol 2 mg/kg at start of procedure; 2 mg/kg for movement, 150-300 mcg/kg/minute propofol infusion if movement persists
Study NCT00333554 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo for DHA
Description: Study placebo given on daily basis to nursing mother (breast milk) or baby as either formula, or capsules (removing content and mixing with food)depending on age of child.